

3. A method according to claim 2 wherein said sample is mammalian blood preferably being derived from a human.
4. A method according to claim 1[, 2 or 3] wherein said Gram-staining indicates the presence of a Gram-negative bacterium in said sample, further comprising determining the rod or coccus character of said bacterium.
5. A method according to claim 4 wherein said character is of the rod type, further comprising hybridising said sample with at least one probe selected from a group of probes capable of hybridising with nucleic acid found *Bacterichia colia*, in *Klebsiella pneumoniae*, in *Klebsiella oxytoca*, in *Serratia marcescens*, in *Enterobacter aerogenes*, in *Enterobacter cloacae*, in *Proteus vulgaris*, in *Proteus mirabilis*, in *Salmonella typhi*, in *Pseudomonas aeruginosa*.
6. A method according to claim 5 wherein said nucleic acid is ribosomal RNA.
7. A method according to claim 6 wherein said probe is having no more than five, preferably no more than two mismatches with a probe selected of a group composed of probes having a sequence GCCTGCCAGTTCGAATG or GTAGCCCTACTCGTAAGG or GAGCAAAGGTATTAACCTTACTCCC or GTTAGCCGTCCCTTCTGG.
8. A method according to claim 4 wherein said character is of the coccus type, further

9. A method according to claim 1[, 2 or 3] wherein said Gram-staining indicates the presence of a Gram-positive bacterium in said sample, further comprising determining the rod or coccus character of said bacterium.

10. A method according to claim 9 wherein said character is of the rod type, further comprising subjecting said sample to treatment with a lysis buffer comprising lysozyme and/or Proteinase K.

11. a method according to claim 9 wherein said character is of the coccus type, further comprising determining a chain-like or clump-like character of said bacteria.

12. A method according to claim 11 wherein said character is chain-like, further comprising subjecting said sample to treatment with a lysis buffer comprising lysozyme.

13. A method according to claim 12 further comprising hybridising said sample with at least one probe selected from a group of probes capable of hybridising with nucleic acid found in *Enterococcus faecalis*, in *Streptococcus pneumoniae*, in *Streptococcus mitis*, in *Streptococcus viridans*, in *Streptococcus ganguis*, in *Enterococcus faecium*.

15. A method according to claim 14 wherein said probe is having no more than five, preferably no more than two mismatches with a probe selected of a group composed of probes having a sequence TTATCCCCCTTGATGGG or AGAGAAGCAAGCTTCTCGTCCG or GCCACTCCTCTTTCCGG.
16. A method according to claim 11 wherein said character is clump-like, further comprising subjecting said sample to treatment with a lysis buffer comprising lysotaphin and/or Proteinase K.
17. A method according to claim 16 further comprising hybridising said sample with at least one probe selected from a group of probes capable of hybridising with nucleic acid found in *Staphylococcus aureus*, in *Staphylococcus haemolyticus*, in *Staphylococcus saprophyticus*.
18. A method according to claim 17 wherein said nucleic acid is ribosomal RNA.
19. A method according to claim 18 wherein said probe is having no more than five, preferably no more than two mismatches with a probe selected of a group composed of probes having a sequence GCTAATGCAGCGCGGATCC or CCGAAGGGGAAGGCTCTA or AGAGAAGCAAGCTTCTCGTCCGTT.
- 10 20. A method according to any of claim[s] 4 to 19] 4 further comprising hybridising said

21. A method according to claim 20 wherein said positive control probe comprising no more than five mismatches with a probe with the sequence GCTGCCTCCGTAGGAGT and/or wherein said negative control probe comprises no more than five mismatches with a probe with the sequence ACTCCTACGGGAGGCAGC.

22. A method according to anyone of claim[s 1 to 21] 1 further comprising a one-step procedure to bind bacteria present in said sample to a microscopic slide and simultaneously fix intracellular structures.

23. A method according to anyone of claim[s 1 to 22] 1 wherein said probe is selected for its reactivity with one or a group of bacterial genera and/or species having congruent susceptibility to antibiotic treatment.

24. A probe detecting or identifying a bacterium in a sample, preferably a clinical sample, said probe designed to hybridise specifically with nucleic acid in bacteria with congruent susceptibility or resistance to antibiotics.

25. A probe according to claim 24 wherein said probe is having no more than five, preferably no more than two mismatches with a probe selected of a group composed of probes having a sequence GCCTGCCAGTTCGAATG or GTAGCCCTACTCGTAAGG or

TTATCCCCCTCTGATGGG or AGAGAAGCAAGCTTCTCGTCCG or
GCCACTCCTTTTCCGG or GCTAATGCAGCGCGGATCC or
CCGAAGGGGAAGGCTCTA or AGAGAAGCAAGCTTCTCGTCCGTT.

26. A diagnostic test kit comprising means for detecting or identifying a bacterium suspected of being present in a sample using a method according to anyone of claims 1 to 23 or using a probe according to claim 24 or 25.

Respectfully submitted,

WELSH & KATZ, LTD.

By
Gerald T. Shekleton
Registration No. 27,466

Dated: October 19, 2000

Welsh & Katz, Ltd.
120 South Riverside Plaza
22nd Floor
Chicago, Illinois 60606
Telephone: 312/655-1500